Capecitabine and Temozolomide for Neuroendocrine Cancers
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This phase II study is designed to assess whether treatment with capecitabine/temozolomide
(CAP/TEM) is safe and effective in treating subjects with progressive, differentiated,
metastatic neuroendocrine tumors (NET). The primary objective of the study is to determine
the radiologic response rate to this regimen in progressive, metastatic, differentiated
neuroendocrine cancers.